November 26, 2018
Authored and Edited by Megan L. Meyers; Samhitha Muralidhar Medatia; Elizabeth D. Ferrill
In Enplas Display Device Corp. v. Seoul Semiconductor Company, No. 16-2599 (Fed. Cir. Nov. 19, 2018), the Federal Circuit vacated and remanded the jury’s $4 million damages award to Seoul Semiconductor Company (SSC), because the majority disagreed with the method of calculating damages. The Court also affirmed the district court’s decision that certain claims of SSC’s patents were not anticipated and affirmed the judgment that Enplas induced infringement related to its lenses used in flat-screen televisions.
Citing AstraZeneca AB v. Apotex Corp., the Court noted that a reasonable royalty “cannot include activities that do not constitute patent infringement.” SSC’s expert opined that Enplas and SSC would have agreed to a $2 to $4 million royalty based on a royalty base including sales of non-accused lenses. The Court determined that this was improper because it would award damages for non-infringing activity. The Court noted that a jury-awarded lump-sum royalty must be based on an estimate of future sales of accused products, not on past sales of non-accused products.
Judge Newman dissented in part regarding the court’s damages holding. Citing Lucent Techs., she noted that “we have never laid down any rigid requirement that damages in all circumstances be limited to specific instances of infringement proven with direct evidence.” She argued that SSC’s expert’s testimony was uncontroverted and should constitute substantial evidence to support the jury’s damages award.
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in February 2024
April 16, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.